

PRECEPTORSHIP PROGRAMME

Urothelial Cancer

Multidisciplinary management,
standards of care and future
perspectives

**ESMO VIRTUAL
PRECEPTORSHIP**

17-18 NOVEMBER 2021

Co-Chairs

Laurence Albiges, France
Ravindran Kanesvaran, Singapore

ESMO VIRTUAL PRECEPTORSHIP PROGRAMME

UROTHELIAL CANCER

Multidisciplinary management, standards of care and future perspectives

17-18 November 2021

CO-CHAIRS: Laurence Albiges, France
Ravindran Kanesvaran, Singapore

SPEAKERS: Joaquim Bellmunt, United States
Lui Shiong Lee, Singapore
Yohann Loriot, France
Darren M. C. Poon, Hong Kong
Thomas B. Powles, United Kingdom
Srikala Sridhar, Canada
Puay Hoon Tan, Singapore

LEARNING OBJECTIVES

- To learn about fundamentals of molecular pathology and diagnosis as contributing factors to heterogeneity in bladder cancer
- To understand essentials in the assessment and multidisciplinary treatment of bladder cancer
- To learn about advances in treatment and novel targets in bladder cancer

ACCREDITATION

The programme of this event has been accredited with **6 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For future details, please refer to esmo.org.

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



All timings are to be considered GMT+8 (Singapore Local Time)

Wednesday, 17 November 2021

15:00-15:10 10'	Welcome and introduction	Laurence Albiges, FR Ravindran Kanesvaran, SG
15:10-15:45 35'	SESSION 1 Pathology and molecular pathology	Chair/Moderator: Ravindran Kanesvaran, SG
15'	Urothelial carcinoma	Puay Hoon Tan, SG
10'	Upper track versus bladder: key differences	Puay Hoon Tan, SG
10'	Discussion	Faculty
15:45-17:30 95'	SESSION 2 Metastatic disease	Chair/Moderator: Laurence Albiges, FR
15'	First-line	Joaquim Bellmunt, US
15'	Second-line and beyond	Yohann Loriot, FR
10'	New agents	Darren M. C. Poon, HK
10'	Discussion	Faculty
16:35-16:45	Break	
45'	Participants clinical case discussion (3x15')	Faculty
17:30-18:05 35'	SESSION 3 Biomarkers	Chair/Moderator Ravindran Kanesvaran, SG
25'	Biomarkers use to inform treatment decisions for MUC	Thomas B. Powles, UK
10'	Discussion	Faculty

Thursday, 18 November 2021

15:00-15:40 40'	SESSION 4 Perioperative management	Chair/Moderator: Ravindran Kanesvaran, SG
15'	What is new in NMIBC	Lui Shiong Lee, SG
15'	Overview of neoadjuvant trials in MIBC	Darren M. C. Poon, HK
10'	Discussion	Faculty
15:40-16:20 40'	SESSION 5 Debate: CPI in adjuvant for MIBC	Chair/Moderator: Laurence Albiges, FR
15'	Pros	Srikala Sridhar, CA
15'	Cons	Thomas B. Powles, UK
10'	Discussion	Faculty
16:20-16:30	Break	

16:30-17:50 80'	SESSION 6 Side effects management	Chair/Moderator: Ravindran Kanesvaran, SG
15'	CPI based regimen toxicity	Laurence Albiges, FR
10'	ADC toxicity	Ravindran Kanesvaran, SG
10'	Discussion	Faculty
45'	Participants clinical case discussion (3x15')	Faculty
17:50-18:00 10'	Conclusion and farewell	Laurence Albiges, FR Ravindran Kanesvaran, SG

Note: Each 15' minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion